Different AcrA glycoforms were separated via hydroxyapatite column chromatography (BioGel HTP, Bio-Rad). Briefly, proteins were loaded in a hydroxyapatite column previously equilibrated with 20 mM sodium phosphate buffer pH 7.5; elution was carried out using a stepwise molarity gradient (30, 40 50, 70, 100, and 400 mM) of sodium phosphate buffer pH 7.5. ScFv antibody F8 was purified from periplasmic extracts by affinity chromatography using protein A Sepharose (GE Healthcare), as described elsewhere ( 
Mass Spectrometric analysis
ESI-MS was measured on Waters micromass ZQ single quadrupole electrospray ionization mass spectrometer. The deconvolution was performed on MassLynx software by using MaxEnt approach. MALDI-TOF was measured on a Bruker AutoFlex II MALDI-TOF mass spectrometer. GlcNAc-AcrA N273Q : Analytical RP-HPLC, t R 19.9 min; ESI-MS, calculated MW = 39444, found 39443 (deconvolution data).
Enzymatic removal of GalNAc residues from the recombinant glycoproteins
[GlcNAc]2-AcrA: Analytical RP-HPLC, t R 19.9 min; ESI-MS, calculated MW = 39633, found 39640 (deconvolution data).
Enzymatic transglycosylation with GlcNAc-containing AcrAs.
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